Back to top

Tale of the Tape

Zacks Equity Research

Akari Therapeutics (AKTX) Shares March Higher, Can It Continue?
April 21, 2017

AKTX

Trades from $3

As of late, it has definitely been a great time to be an investor in Akari Therapeutics PLC (AKTX - Free Report) . The stock has moved higher by 111.5% in the past month, while it is also above its 20 Day SMA too. This combination of strong price performance and favorable technical, could suggest that the stock may be on the right path.

We certainly think that this might be the case, particularly if you consider AKTX’s recent earnings estimate revision activity. From this look, the company’s future is quite favorable; as AKTX has earned itself a Zacks Rank #1 (Strong Buy), meaning that its recent run may continue for a bit longer, and that this isn’t the top for the in-focus company.You can seethe complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Zacks' 2017 IPO Watch List  

 Before looking into the stocks mentioned above, you may want to get a head start on potential tech IPOs that are popping up on Zacks' radar. Imagine being in the first wave of investors to jump on a company with almost unlimited growth potential? This Special Report gives you the current scoop on 5 that may go public at any time.

One has driven from 0 to a $68 billion valuation in 8 years. Four others are a little less obvious but already show jaw-dropping growth. Download this IPO Watch List today for free >>





In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Akari Therapeutics PLC (AKTX) - free report >>